ArticleHeliyon2025
Effect of Reablement Strategies targeting Sarcopenia (ReStart-S) on sarcopenic older adults residing in long term care settings: A protocol for cluster randomized trial.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cluster randomized trial of reablement strategies targeting sarcopenia (ReStart-S) in long-term care settings.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Trial
- Exploration of Pathogenesis and Cutting-Edge Treatment Strategies of Sarcopenia: A Narrative Review.Clinical interventions in aging · 2025Review
- The association between living habits, physical activity level and sarcopenia in chinese older adults with type 2 diabetes mellitus: a cross-sectional study.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prevalence of sarcopenia is high among older adults residing in long-term care settings (LTCS). Guidelines to manage sarcopenia cannot be directly implemented among sarcopenic older adults residing in LTCS. Objectives: To examine the effectiveness of a codesigned Reablement Strategies targeting Sarcopenia (ReStart-S) program on muscle parameters, physical performance, blood biomarkers and quality of life among sarcopenic older adults residing in LTCS. Methods: The study is a cluster randomized trial that will take place in LTCS. A total of 78 sarcopenic older adults will be included, selected through convenience sampling, and diagnosed using the Asian Working Group for Sarcopenia 2019 criteria. The LTCS clusters will be randomized into intervention and control groups. The participants in the intervention group will receive the ReStart-S multicomponent exercise intervention twice a week for a total of six weeks, while those in the control group will continue with their usual daily activities. The primary outcome will be grip strength, and the secondary outcomes will include a short physical performance battery, muscle mass, C-terminal agrin fragment, and quality of life as assessed through the sarcopenia and quality of life-Kannada version questionnaire. The outcomes will be measured at week 0, week 6, week 12, and week 18. Conclusion: ReStart-S program if found to be effective could be implemented globally to manage sarcopenia and promote healthy ageing in older adults, enhancing their independence in LTCS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.